Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC Patients

This ongoing Phase 2 trial, sponsored by Memorial Sloan Kettering Cancer Center, investigates the efficacy of adding liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy, which includes anti-PD-(L)1 based immunotherapy and platinum-based chemotherapy, in patients with metastatic non-small cell lung cancer (NSCLC). The study aims to enroll 68 participants, with a primary endpoint of median progression-free survival. The trial began on December 9, 2022, and is expected to reach primary completion by December 9, 2026. Secondary endpoints and safety data will be evaluated, but specific results and statistical analyses are not yet available. Clinicians should consider the potential of L-SABR as an adjunctive treatment in metastatic NSCLC pending further data.

Imagine facing metastatic lung cancer, where the disease has spread beyond the lungs. This is a tough battle, as traditional treatments often struggle to keep the cancer at bay. A new study is testing whether adding a specific type of radiation therapy, called liver stereotactic ablative radiotherapy, to standard drug treatments can provide better outcomes for patients. The goal is to see if this combination can help patients live longer without their cancer progressing. If successful, this approach could offer new hope for those with advanced lung cancer, potentially giving them more quality time with family and friends. However, it’s important to remember that this is still in the testing phase, and results can vary. More research will help clarify the benefits and risks, but for now, this study shines a light on promising new options for patients in need.